▶ TB-500 · SUBTOPIC · SAFETY PROFILE
TB-500 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of TB-500.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of TB-500. Severity, frequency, and attribution depend on the source publication.
- Limited human safety data
- Injection-site reactions reported anecdotally
- Theoretical fatigue or lethargy in early administration
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for TB-500.
- Anticoagulants (theoretical, due to angiogenic activity · unstudied)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for TB-500 in the published record:
- Active malignancy (theoretical, due to angiogenic + cell-migration mechanism)
- Pregnancy/lactation (unstudied)
FDA REGULATORY STATUS
Not FDA-approved for any human use. Research-use only.
WADA REGULATORY STATUS
Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) · Thymosin Beta-4 and its derivatives named explicitly in the 2018 Prohibited List update.
SAFETY Q+A FROM LITERATURE
▶ Is TB-500 banned by WADA?
Yes. Thymosin Beta-4 and its derivatives, including TB-500, were named explicitly under Section S2 in the 2018 WADA Prohibited List update. Prohibited at all times (in-competition and out-of-competition).
▶ Is TB-500 FDA-approved?
No. TB-500 is not FDA-approved for any human therapeutic use. Research-grade material is supplied for laboratory use only.
▶ Side effects of TB-500?
Limited human safety data. Animal toxicology shows a wide therapeutic window. Theoretical concerns include unstudied effects in active malignancy (due to angiogenic + cell-migration mechanism) and pregnancy.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010. PMID 20179146. link
- Bock-Marquette I, Saxena A, White MD, et al.. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004. PMID 15565145. link
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005. PMID 16099219. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19